Eye Diseases Clinical Trial
— AECSOfficial title:
The Cohort Study of Eye Health of Aging People
Aging is a major risk factor for many blind-causing eye diseases, e.g., glaucoma, age-related cataracts, and age-related macular degeneration. With the population aging, the impact of lifestyle changes (less time spent outdoors, increasingly sedentary lifestyles, and unhealthy eating habits) on the eye health of the elderly needs further research. This study focuses on establishing a cohort of elderly subjects with normal vision and ocular structure at baseline. The main goal is to study the risk factors for common eye diseases in Chinese elderly population while providing normal-controlled clinical and genomic data for other clinical studies on eye diseases.
Status | Recruiting |
Enrollment | 2500 |
Est. completion date | February 19, 2029 |
Est. primary completion date | February 19, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 95 Years |
Eligibility | Inclusion criteria: 1. Be able and willing to consent to the qualification and the follow-up phases of the study; 2. Be able to undergo yearly examinations for =5 years; 3. Age is older than 60 years; 4. Best-corrected visual acuity of both eyes is better than 20/32; 5. Intraocular pressure (non-contact tonometer) is between 10-21 mmHg; 6. Except for mild cataracts, no other structural abnormalities of the eye are found. 7. have fundus photographs of adequate quality as assessed with a standardized protocol by the University of Wisconsin Fundus Photograph Reading Center. Exclusion Criteria: 1. the presence of ocular disease in either eye, except for mild cataracts and ametropia; 2. previous retinal or other ocular surgical procedures (other than cataract extraction and capsulotomy); 3. a chronic requirement for any systemic or ocular medication administered for other diseases and known to be toxic to the retina or optic nerve; 4. cataract surgery within three months or capsulotomy within six weeks before the qualification visit; 5. any systemic disease with a poor 5-year survival prognosis. |
Country | Name | City | State |
---|---|---|---|
China | Zhongshan Ophthalmic Center, Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Zhongshan Ophthalmic Center, Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence of visual impairment at Year 1 | The best corrected visual acuity is worse than 15/25. | 1 Year | |
Primary | The incidence of visual impairment at Year 2 | The best corrected visual acuity is worse than 15/25. | 2 Year | |
Primary | The incidence of visual impairment at Year 3 | The best corrected visual acuity is worse than 15/25. | 3 Year | |
Primary | The incidence of visual impairment at Year 4 | The best corrected visual acuity is worse than 15/25. | 4 Year | |
Primary | The incidence of visual impairment at Year 5 | The best corrected visual acuity is worse than 15/25. | 5 Year | |
Secondary | Change from Baseline Best Corrected Visual Acuity at 1 Year | 1 Year | ||
Secondary | Change from Baseline Best Corrected Visual Acuity at 2 Year | 2 Year | ||
Secondary | Change from Baseline Best Corrected Visual Acuity at 3 Year | 3 Year | ||
Secondary | Change from Baseline Best Corrected Visual Acuity at 4 Year | 4 Year | ||
Secondary | Change from Baseline Best Corrected Visual Acuity at 5 Year | 5 Year | ||
Secondary | The incidence of age-related cataract at Year 1 | Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). | 1 Year | |
Secondary | The incidence of age-related cataract at Year 2 | Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). | 1 Year | |
Secondary | The incidence of age-related cataract at Year 3 | Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). | 3 Year | |
Secondary | The incidence of age-related cataract at Year 4 | Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). | 4 Year | |
Secondary | The incidence of age-related cataract at Year 5 | Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). | 5 Year | |
Secondary | The incidence of age-related macular degeneration at Year 1 | The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. | 1 Year | |
Secondary | The incidence of age-related macular degeneration at Year 2 | The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. | 2 Year | |
Secondary | The incidence of age-related macular degeneration at Year 3 | The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. | 3 Year | |
Secondary | The incidence of age-related macular degeneration at Year 4 | The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. | 4 Year | |
Secondary | The incidence of age-related macular degeneration at Year 5 | The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. | 5 Year | |
Secondary | The incidence of glaucoma at Year 1 | 1 Year | ||
Secondary | The incidence of glaucoma at Year 2 | 2 Year | ||
Secondary | The incidence of glaucoma at Year 3 | 3 Year | ||
Secondary | The incidence of glaucoma at Year 4 | 4 Year | ||
Secondary | The incidence of glaucoma at Year 5 | 5 Year | ||
Secondary | The incidence of diabetic retinopathy at Year 1 | 1 Year | ||
Secondary | The incidence of diabetic retinopathy at Year 2 | 2 Year | ||
Secondary | The incidence of diabetic retinopathy at Year 3 | 3 Year | ||
Secondary | The incidence of diabetic retinopathy at Year 4 | 4 Year | ||
Secondary | The incidence of diabetic retinopathy at Year 5 | 5 Year | ||
Secondary | The incidence of myopia-related fundus changes at Year 1 | 1 Year | ||
Secondary | The incidence of myopia-related fundus changes at Year 2 | 2 Year | ||
Secondary | The incidence of myopia-related fundus changes at Year 3 | 3 Year | ||
Secondary | The incidence of myopia-related fundus changes at Year 4 | 4 Year | ||
Secondary | The incidence of myopia-related fundus changes at Year 5 | 5 Year | ||
Secondary | Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 1 | Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. | 1 Year | |
Secondary | Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 2 | Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. | 2 Year | |
Secondary | Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 3 | Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. | 3 Year | |
Secondary | Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 4 | Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. | 4 Year | |
Secondary | Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 5 | Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. | 5 Year | |
Secondary | Change from Baseline Self-scoring of the Quality of Life at Year 1 | Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. | 1 Year | |
Secondary | Change from Baseline Self-scoring of the Quality of Life at Year 2 | Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. | 2 Year | |
Secondary | Change from Baseline Self-scoring of the Quality of Life at Year 3 | Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. | 3 Year | |
Secondary | Change from Baseline Self-scoring of the Quality of Life at Year 4 | Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. | 4 Year | |
Secondary | Change from Baseline Self-scoring of the Quality of Life at Year 5 | Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. | 5 Year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Completed |
NCT02811692 -
Study for Collection of Aflibercept Data in Routine Practice
|
||
Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT04799704 -
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
|
||
Recruiting |
NCT05876689 -
Swept Source OCT Imaging With the DREAM VG-OCT
|
||
Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT04150432 -
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children
|
N/A | |
Not yet recruiting |
NCT05550740 -
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
|
N/A | |
Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
Completed |
NCT00333203 -
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
|
Phase 3 | |
Not yet recruiting |
NCT05565547 -
Multimodal Equipment for Teleophthalmology Assessment (META)
|
||
Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Completed |
NCT05211089 -
Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
|
||
Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|